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Rheumatoid arthritis
AbstrAct
Objectives to describe the development and assess the 
psychometric properties of the novel ‘Symptoms in Persons 
at risk of rheumatoid arthritis’ (SParra) questionnaire 
in individuals at risk of rheumatoid arthritis (ra) and to 
quantify their symptoms.
Methods the questionnaire items were derived from a 
qualitative study in patients with seropositive arthralgia. 
the questionnaire was administered to 219 individuals 
at risk of ra on the basis of symptoms or autoantibody 
positivity: 74% rheumatoid factor and/or anticitrullinated 
protein antibodies positive, 26% seronegative. Validity, 
reliability and responsiveness were assessed. eighteen 
first degree relatives (FDr) of patients with ra were used 
for comparison.
Results Face and content validity were high. the test-
retest showed good agreement and reliability (1 week and 
6 months). Overall, construct validity was low to moderate, 
with higher values for concurrent validity, suggesting that 
some questions reflect symptom content not captured 
with regular Visual analogue Scale pain/well-being. 
responsiveness was low (small subgroup). Finally, the 
burden of symptoms in both seronegative and seropositive 
at risk individuals was high, with pain, stiffness and fatigue 
being the most common ones with a major impact on daily 
functioning. the FDr cohort (mostly healthy individuals) 
showed a lower burden of symptoms; however, the 
distribution of symptoms was similar.
Conclusions the SParra questionnaire has good 
psychometric properties and can add information to 
currently available clinical measures in individuals at risk 
of ra. the studied group had a high burden and impact 
of symptoms. Future studies should evaluate whether 
SParra data can improve the prediction of ra in at risk 
individuals.
InTROduCTIOn
A range of symptoms can be present in indi-
viduals at risk of rheumatoid arthritis (RA). 
These individuals are usually defined based on 
either autoantibody positivity or symptoms. In 
seropositive at risk persons, symptoms usually 
occur later than seropositivity.1 2 However, 
information on location, timing and severity 
of symptoms is still largely lacking.3 
Symptoms such as joint pain, swelling and 
morning stiffness represent key elements in 
the diagnosis of RA. Clinicians have tried 
to use these and other symptoms to identify 
those at risk of RA before they fulfil classi-
fication criteria for this condition.4 A Euro-
pean League Against Rheumatism (EULAR) 
taskforce recently outlined symptoms that 
were deemed most relevant in differentiating 
those at risk of developing RA (also known 
as ‘clinically suspect arthralgia’ (CSA)5) from 
other patients with non-specific joint symp-
toms.6 The criteria set for CSA were based 
Key messages
What is already known about this subject?
 ► a wide range of symptoms can be present in 
individuals at risk of rheumatoid arthritis (ra), 
including extra-articular symptoms.
 ► these symptoms can be severe and disabling.
What does this study add?
 ► this study used data from qualitative focus 
interviews to quantify symptoms in individuals at 
risk of ra.
 ► the ‘Symptoms in Persons at risk of rheumatoid 
arthritis’ (SParra) questionnaire provides 
information on location, timing and severity of 
these symptoms in a large international sample of 
individuals at risk of developing ra.
How might this impact on clinical practice?
 ► the SParra questionnaire can be used to 
document symptoms in studies of persons at risk 
of ra.
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on expert opinion and have shown value in predicting 
arthritis.7
Qualitative research in individuals at risk of RA provided 
a different starting point to evaluate symptoms using 
the experience of the affected persons to understand 
the range of their symptomatology. With this approach, 
multiple focus group interviews were performed in 
patients with seropositive arthralgia.8–10 Besides symp-
toms originating from the joints, additional extra-artic-
ular themes emerged such as fatigue, distress and loss 
of motor control, with a reported major impact on daily 
functioning. The presumed impact of such early symp-
toms is underscored by increased sick leave and medical 
ambulatory costs long before diagnosis of RA.11 12
The ‘Symptoms in Persons At Risk of Rheumatoid 
Arthritis’ (SPARRA) questionnaire was developed based 
on data from our previous qualitative study.9 The aim 
of the present study was to describe the developmental 
process and test the psychometric properties of the 
SPARRA questionnaire in an international convenience 
sample of individuals at risk of RA (both autoantibody 
positive and negative) and to quantify and describe their 
symptoms based on this questionnaire.
PaTIenTs and MeTHOds
The development of the sPaRRa questionnaire
The content of the SPARRA questionnaire is based on focus 
group interviews in 15 patients with seropositive arthralgia 
and 11 patients with early RA with whom initial symptoms 
prior to the diagnosis of RA were explored.9 These semis-
tructured interviews were conducted to explore perceptions 
of symptoms, impact of symptoms and reactions to symp-
toms and continued until thematic saturation was reached. 
The content of the questionnaire was also informed by a 
previous review of the literature related to the earliest symp-
toms of RA4 and prior research describing domains that 
were deemed important in predictive algorithms in these 
at-risk individuals.13 14 The emerging themes were grouped 
and the most noteworthy and frequently occurring catego-
ries were selected. Feedback from the study team (two rheu-
matologists, one epidemiologist, one expert on psycholog-
ical testing and two research patient partners) was used to 
discuss which symptoms to be captured within the question-
naire, discuss realistic timeframes for symptom duration 
and the number/format of answer categories for severity 
and impact of the symptoms, taking into account reported 
variation in each of the domains by individuals from the 
focus group interviews. Afterwards, four rheumatologists 
from different countries, working in the field of the at-risk 
phase of RA but who were not otherwise involved in the 
project, gave their feedback on the questionnaire. The final 
questionnaire included 13 symptoms, for which severity and 
impact were described from none to severe and no to high, 
respectively. Additional questions were aimed at capturing 
location and pattern of joint pain (if present) and the pres-
ence of morning stiffness. Recently, data on symptoms in 
the at-risk phase of RA appeared in literature from two 
other cohorts and one review. These studies contain items 
on functional limitations, such as difficulty making a fist, 
which are possibly additive to the SPARRA questionnaire 
which only contains the following symptoms on function: 
‘weakness or loss of motor control’ and ‘impact of symp-
toms on daily functioning’.15–17 The questionnaire’s design 
and content was thereafter discussed with patient research 
partners from both Amsterdam and Birmingham to assess 
face validity which led to only minor comments and small 
modifications.
Subsequently, the questionnaire was translated from 
English into Dutch, Swedish, German and French by at 
least one native speaker. These native speakers were part of 
the study teams at the different centres and had knowledge 
of research in individuals at risk of developing RA, but were 
not part of the study team that performed the focus inter-
views leading to the questionnaire development. There-
after, another researcher from that study team translated 
it back to English, blinded for the original wording of the 
items, to complete the formal forward-backward approach 
as presented by the WHO (steps 1 and 2, except for the 
fact that back-translation was not performed by a whole 
expert panel).18 All inconsistencies were resolved in collab-
oration with a member of the original focus group inter-
view team (LvT), by referring to the original wording in the 
focus groups. Cross-cultural adaptations were made taking 
into account cultural aspects of presenting joint symptoms 
within the different countries.19 As a preliminary pilot test, 
the Dutch prefinal version of the questionnaire was admin-
istered to 30 seropositive individuals with arthralgia from 
the Netherlands, which did not change the question-
naire (WHO steps 3 and 4, no cognitive interviewing was 
performed).18 To pre-empt any missing symptoms indi-
viduals had the possibility of adding up to two additional 
symptoms that they thought were relevant. See table 1 for 
an outline of the questionnaire (complete questionnaire 
and translated versions presented as online supplementary 
figures 1–5).
study participants
To test the psychometric properties of the SPARRA ques-
tionnaire, individuals at risk of developing RA defined 
as individuals with RA-specific autoantibodies (anticit-
rullinated protein antibodies (ACPA) and/or rheuma-
toid factor (RF)) or the presence of relevant symptoms 
(ie, individuals with CSA based on clinical expertise in 
the different centres with or without RA-specific anti-
bodies) were selected from four European centres: 
Reade, Amsterdam (n=125) (further called the Nether-
lands), Sandwell and West Birmingham Hospitals and 
the University Hospitals Birmingham (n=69) (UK), 
Karolinska University Hospital (n=15) (Sweden) and the 
Medical University of Vienna (n=10) (Austria). We have 
used an international sample of patients at risk for RA, 
mainly containing consecutive cohort patients (Nether-
lands, UK, Sweden, in total 88%) and complemented 
by a convenience sample from Austria and Switzerland. 
Please note that in Austria, patients were recruited from 
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their ‘pre-arthritis’ cohort and by additionally searching 
through their clinical database for patients who were 
ACPA-positive and/or RF-positive without a diagnosis of 
arthritis. In Switzerland, individuals could complete a 
SPARRA questionnaire at any time when they visited for 
a yearly cohort follow-up. All cohorts were set up to char-
acterise individuals at risk of developing RA and included 
individuals without prior arthritis (see online supple-
mentary table 1).20 21 Arthritis was assessed clinically (by 
a rheumatologist in all cohorts) by presence of at least 
one swollen joint: no confirmation by ultrasonography 
or MRI was used. A cohort of 18 first degree relatives 
(FDR) of patients with RA from the University Hospital 
of Geneva (Switzerland) was used as comparison, since 
they also represent a group of individuals at risk of devel-
oping RA which the SPARRA questionnaire is aimed at. 
This cohort was dealt with separately, since the individ-
uals were recruited based on the fact that they were FDR 
and not because of symptoms or antibodies and thus 
included mostly healthy individuals with an increased 
risk of RA. Individuals were included between November 
2014 and December 2016.
study procedures
At baseline, individuals completed the SPARRA question-
naire and had clinical data collected, including antibody 
status, total painful (tender joint count 44) and swollen 
joints (swollen joint count 44), family history, symptom 
duration, smoking status, Visual Analogue Scales (VAS, 
ranged 0–100) for pain, patient global assessment and 
fatigue. Detailed data on comorbidities and medication 
have not been consistently assessed across the cohorts 
for the present study. A subgroup of individuals had a 
follow-up measurement (test-retest) after 1 week and 
6 months. Questionnaires completed at the time of or 
after clinical arthritis development (confirmed by a rheu-
matologist) were discarded for the current analysis. The 
study was approved by relevant Ethics Committees and all 
individuals gave written informed consent.
Psychometric properties
content validity
Relevant medical articles on symptoms in the at risk phase 
of RA were compared with the questionnaire items to see 
if all relevant facets of the construct had been captured.
construct validity
We performed correlations between baseline question-
naire items and clinical parameters that were deemed to 
be associated based on expert opinion (seven representa-
tives from all centres). We divided these into items with a 
very close match (concurrent validity, eg, the item fatigue 
compared with VAS fatigue) and items with less close a 
match (construct validity). Individuals had to complete 
the questionnaire within 2 weeks of clinical measure-
ments.
Table 1 Outline of the SPARRA questionnaire
Per symptom (see right), the following questions are asked:
1. Over the past month how many days of the month have you had 
(symptom)?
2. Over the past month how much (symptom) have you had?
3. What impact has this (symptom) had on your ability to carry out daily 
activities (eg, work, household chores, childcare, social activities)?
4. Where did you feel the [symptoms 1 to 9]
Answer categories:
1. 0 days, 1–5 days, 6–16 days, 16–30 days
2. None, mild, moderate, severe
3. No impact, small impact, moderate impact, large impact
4. Hand (one or both), arm (one or both), foot (one or both), leg (one or both)
1. Joint pain (symptoms)
2. Joint swelling
3. Joint stiffness
4. Burning sensations
5. Tingling sensations
6. Numbness
7. Changes in skin colour over joints
8. Muscle cramps
9. Weakness or loss of strength
10. Fatigue
11. Emotional distress
12. Concentration difficulties
13. Sleep problems
Additional questions:
 ► Description of joint pain (burning, sharp/stabbing, aching, other)
 ► Movement of joint pain (no, arms to legs, legs to arms, one side to the 
other)
 ► Presence of morning stiffness (no, <1 hour, 1–2 hours, all morning)
Rate the average joint pain over the last month in different body areas:
 ► Answer categories: no pain, mild moderate, severe
 ► Fingers (left/right), wrist (left/right), elbow (left/right), shoulder (left/right), 
hip (left/right), knee (left/right), ankle (left/right), toes (left/right), neck, 
back
What is the pattern of symptom development since the time they first began 
(see patterns on the right; patients could also draw a pattern themselves)
intensity
of
symptoms
time
A
Intensity
of
symptoms
time
B
intensity
of
symptoms
time
C
intensity
of
symptoms
time
D
Note: full questionnaire (with translations) added as online supplementary material. 
SPARRA, Symptoms in Persons At Risk for Rheumatoid Arthritis. 
 o
n
 27 June 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000641 on 21 M
ay 2018. Downloaded from
 
4 van Beers-tas MH, et al. RMD Open 2018;4:e000641. doi:10.1136/rmdopen-2017-000641
RMD Open
agreement and reliability
Test-retest analyses were performed in a subgroup of 
individuals that completed a second test within 7–14 
days and/or after 6 months. The retest questionnaire was 
only sent after return of the first questionnaire. The anal-
yses were performed in questions not containing time 
elements. Also, we described the scale reliability at base-
line, that is, looking at how closely related the items in 
the questionnaire are as a group.
responsiveness
This can only be tested in individuals with expected 
change in their disease status, in our case VAS scores over 
a time period of 6 months. No formal clinically relevant 
VAS score changes have been described in individuals at 
risk of developing RA. We chose a change of 11 mm as 
sometimes used in an adult rheumatology setting,22, and 
we measured a second arbitrary cut-off of 25 mm, since 
the questionnaire items are on a 4-point scale. We only 
analysed questionnaire items that were concurrent with 
the VAS scores. The questionnaire had to be completed 
within 2 weeks from the clinical measurements.
statistical analyses
construct validity
Correlations were calculated using the Spearman’s rank 
correlation coefficient. Statistical significance was set as 
a p value less than 0.05. The VAS scores were used as 
continuous data. Interpretation: 0–0.30 small, 0.3–0.50 
medium, 0.50–1 large.23
test-retest agreement and reliability
The percentage of agreement in the questionnaire items 
was given for questions on symptom severity and impact, 
and the Cohen’s weighted kappa (reliability) was meas-
ured.24 Interpretation: <0 no, 0–0.20 slight, 0.21–0.40 
fair, 0.41–0.60 moderate, 0.61–0.80 substantial and 
0.81–1 almost perfect agreement.25 26 Scale reliability was 
described with the Cronbach’s alpha.
responsiveness
The Wilcoxon signed-rank test was used to analyse signif-
icant differences between questionnaire items over the 
6-month period, taking p<0.05 as significance level.
Handling missing data
All questions in the questionnaire follow the same 
pattern (table 1). If subquestions ‘a’ (duration of the 
symptom over the past month) were missing and ‘b–d’ 
were also missing, then ‘a’ was set as 0 days. Equally, if ‘a’ 
was set as 0 days, then ‘b–d’ were set as none, no impact 
and not filled in, respectively. Instead, if ‘b–d’ were filled 
out while ‘a’ was missing, then we assumed the worst case 
scenario and set ‘a’ as 16–30 days.
All analyses were performed with SPSS V.21 (IBM, 
Armonk, New York, USA), except for the Cohen’s 
weighted kappa’s which were computed using Stata 
V.13.1 (Stata 2013, College Station, Texas, USA).
Frequency and impact of symptoms in the sPaRRa 
questionnaire
Finally, we analysed data from individuals who were 
ACPA-positive (with or without RF), only RF-positive and 
those included in the cohort due to specific symptoms 
(seronegative CSA). Percentages of symptom duration 
in the last month (dichotomised to 0–15 days and 16 or 
more days), severity (none/mild vs moderate/severe) 
and impact (no/small vs moderate/large) were given for 
these groups and information on joint pain location and 
patterns was described.
ResulTs
study population
Two hundred and nineteen individuals completed the 
SPARRA questionnaire in 4 European centres, with 18 
FDR of patients with RA as comparison (online supple-
mentary table 2). Half of the individuals (excluding the 
FDR) were ACPA-positive (with or without RF), 24% were 
only RF-positive and 26% were seronegative with CSA 
(table 2). The mean age of these study participants was 
49 years (SD 13.2) and the median duration of symptoms 
was 20 months (25th–75th percentile 8–56).
Content validity
The items in the questionnaire represent symptoms that 
are important for individuals at risk of RA.13 14 27–29 Liter-
ature search did not identify any additional symptoms 
describing the at risk phase, except for self-reported func-
tional limitation as part of a tool to detect early inflam-
matory arthritis30 and difficulty in making a fist at phys-
ical examination in individuals with CSA.6 In addition 
to the seropositive individuals, we also selected seroneg-
ative individuals with CSA and FDRs to achieve a good 
representation of the at risk population. To make sure 
that no key symptoms were omitted, in addition to the 
13 predefined symptoms, individuals had the option of 
adding two symptoms. Forty-three out of the 219 individ-
uals used this option (of whom 14 reported two options). 
Themes (reported at least twice) were: pain/inflamma-
tion around tendons or myalgia (n=7), pain only while 
using the joint (n=4), dry eyes (n=4), functional limi-
tations (n=2), itching skin spots (n=2) and swelling in 
the groin or legs (n=2). However, many of them did not 
describe new symptoms (n=16 alternative diagnosis that 
they felt explained their symptoms such as osteoarthritis 
or hernia, n=5 explanatory description, n=2 unclear).
Construct validity (relation to clinical parameters)
Analyses were performed in 208 individuals, since 11 did 
not have clinical data collected within 2 weeks from the 
baseline questionnaire. Overall, the correlation between 
questionnaire items and clinical parameters (VAS pain, 
VAS global assessment and VAS fatigue) was medium to 
large with Spearman coefficients ranging from 0.38 to 
0.63 (online supplementary table 3, all statistically signif-
icant). Correlations were higher when strictly looking 
at concurrent validity (0.58–0.63). The percentage of 
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missing values in the questionnaire items was 1% (15 
missing questions were set on the worst case scenario, 91 
were set on no symptoms) and in the clinical parameters 
3%.
Test-retest reliability and agreement and scale reliability
Analyses after 1 week were performed in 51 individuals 
(20 ACPA+, 26 RF+, 5 seronegative) and after 6 months 
in 90 individuals (37 ACPA+, 30 RF+, 23 seronegative). 
The median time difference in the latter 90 individuals 
between the questionnaires was 6 months (25th–75th 
percentiles: 5–10). Thirty-eight individuals had a retest 
after both 1 week and 6 months. Overall, the test-retest 
agreement for the questions was good to excellent (88%–
98%) after 1 week, and good reliability with Cohen’s 
weighted kappa’s between 0.60 and 0.90 was found 
(table 3). After 6 months, the agreement was 73%–91%, 
with lower overall kappa's between 0.09 and 0.62. Less 
than 1% of the data was missing (14 missing questions 
were set on the worst case scenario, 30 were set on no 
symptoms). Subgroup analysis was not feasible due to low 
numbers. The Cronbach’s alpha for all items on dura-
tion, severity and impact was 0.859, 0.874 and 0.908, 
respectively (0.958 if all items were combined).
Responsiveness
Seventy-four individuals had clinical and questionnaire 
data after a follow-up of 6 months and within 2 weeks 
apart. Of these, 31 individuals had a VAS pain change of 
11 mm and 12 individuals a VAS pain change of 25 mm; 
equivalent data for VAS fatigue were 32 individuals and 
16 individuals (17% missing VAS change scores). The 
Wilcoxon signed-rank test for the questionnaire items 
joint pain severity and impact was non-significant when 
using both cut-off points for VAS pain (p=0.46 and 
p=0.24, respectively for cut-off 11 mm and both p=0.43 
for cut-off 25 mm). Also, no statistically significant differ-
ences were found for fatigue severity/impact for the 
VAS fatigue (p=0.21 and p=0.63, respectively, for cut-off 
11 mm, and p=0.11 and p=0.15, respectively, for cut-off 
25 mm).
Frequency and impact of symptoms
The frequency of symptoms and their impact in the indi-
viduals at risk of RA was high (table 4). Overall, presence 
of symptoms was reported more often by the seronega-
tive individuals with CSA, followed by the ACPA-positive 
and then the RF-positive group (except for fatigue which 
occurred more often in ACPA-positive individuals). In all 
three groups, the percentage of individuals with symp-
toms at least 16 days in the past month was highest for 
joint pain (37%–72%), joint stiffness (34%–68%), weak-
ness or loss of strength (21%–35%) and fatigue (28%–
39%). The severity and impact were reported similarly 
across the three groups with the exception of burning 
Table 2 Baseline characteristics (n=219)
Variable
ACPA-positive 
individuals* (n=109)
RF-positive 
individuals*
(n=53)
Seronegative 
individuals with CSA
(n=57)
FDRs of patients with 
RA†
(n=18)
Age‡ 49 (12.9) 54 (13.2) 45 (12.6) 57 (9.5)
Females (%) 72 64 72 89
Symptom duration 
(months)§
23 (10–52) 30 (12–60) 11 (4–39) 22 (7–51)
Tender joint count (44 
joints)
0 (0–2) 0 (0–2) 2 (0–7) 1 (0–3)
VAS pain (mm)§ 18 (2–56) 27 (3–47) 56 (34–71) ND
VAS patient global 
assessment (mm)§ 
28 (3–56) 22 (0–49) 48 (25–69) ND
VAS fatigue (mm)§ 50 (9–80) 33 (6–59) 65 (40–82) ND
Current smoking (%) 24 15 25 17
FDR with RA (%)§ 29 21 28 100
*ACPA-positive individuals: with or without RF positivity, RF-positive individuals: only RF-positive.
†FDRs of patients from Switzerland with RA were used as comparison cohort.
‡Mean (SD), all other continuous variables mentioned as median (25th–75th percentile).
§Missing values; 2% for VAS global and family history, 3% for VAS pain, 4% for VAS fatigue, 6% for symptom duration, one individual for RF 
(marked as ACPA positive only now).
Netherlands: ACPA+ n=71; RF+ n=40; seronegative n=14.
UK: ACPA+ n=21; RF+ n=8; seronegative n=40.
Sweden: ACPA+ n=15; RF+ n=0; seronegative n=0.
Austria: ACPA+ n=2; RF+ n=5; seronegative n=3.
Switzerland: ACPA+ n=6; RF+ n=1; seronegative n=11.
ACPA, anticitrullinated protein antibodies; CSA, clinically suspect arthralgia; FDR, first degree relative; ND, not done; RA, rheumatoid 
arthritis; RF, rheumatoid factor; VAS: Visual Analogue Scale. 
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and tingling sensations and muscle cramps, which had 
a lower frequency in ACPA-positive individuals, but a 
higher impact and severity.
Joint pain was mostly reported in the fingers 
(ACPA+ 58%, RF+ 52%, seronegative with CSA 65%); 
however, the percentage of neck and back pain was also 
high (ACPA+ 39%, RF+ 46%, seronegative with CSA 
47% and ACPA+ 50%, RF+ 52%, seronegative with CSA 
57%, respectively) (figure 1). Usually, this joint pain 
was described as aching, symmetric and only one-third 
reported them as mild. The location of joint pain had a 
similar distribution across all groups.
Finally, we evaluated the pattern of joint pain in the 
period preceding the first questionnaire (table 1). Joint 
pain rapidly increasing and then remaining constant was 
reported by 9% (pattern A), joint pain gradually increasing 
over time by 16% (pattern B) and a more intermittent 
pattern by 53% (respectively 23% and 30% for in between 
periods without pain (D) and symptoms coming and 
going but always some pain present (C)) (see table 4 for 
classification by antibody positivity or negativity). Fourteen 
individuals (6%) had missing data. The remainder of the 
individuals chose the option of either drawing a pattern 
themselves or describing it. Of those, one was similar to A, 
five similar to C and six to D. Of the remaining 25, 6 had 
no symptoms, 11 had a peak in the beginning and then 
declining symptoms (mostly to 0), 3 had a combination 
of the intermittent patterns, 1 reported an intermittent 
pattern with no remaining symptoms afterwards, 3 were 
unclear and the last individual filled in both A and C.
Table 3 Test-retest analysis of the SPARRA questionnaire (n=51 after 1 week, n=90 after 6 months)
Items
% agreement* Weighted kappa
Percentage with the 
symptom†
1 week 6 months 1 week 6 months 1 week 6 months
Joint pain: severity‡/impact§ 84/92 77/77 0.60/0.78 0.37/0.41 75 80
Joint swelling: severity/impact 95/94 83/83 0.80/0.77 0.42/0.44 28 37
Joint stiffness: severity/impact 88/93 79/81 0.71/0.78 0.47/0.45 69 74
Burning sensations: severity/impact 90/92 81/83 0.64/0.61 0.43/0.42 20 33
Tingling sensations: severity/impact 90/93 85/84 0.62/0.64 0.53/0.35 41 40
Numbness: severity/impact 90/94 83/85 0.53/0.67 0.27/0.27 26 27
Changes in skin colour: severity/
impact
96/98 83/91 0.67/0.71 0.09/0.20 20 20
Muscle cramps: severity/impact 92/95 84/87 0.63/0.71 0.43/0.39 28 36
Weakness or loss of strength: 
severity/impact
92/93 78/76 0.81/0.81 0.43/0.34 57 56
Fatigue: severity/impact 93/92 80/79 0.81/0.82 0.52/0.50 69 63
Emotional distress: severity/impact 93/95 77/80 0.78/0.83 0.37/0.41 47 39
Concentration difficulties: severity/
impact
93/94 86/87 0.76/0.78 0.58/0.58 33 39
Sleep problems: severity/impact 90/93 81/83 0.77/0.80 0.54/0.54 55 49
Left fingers/right fingers 91/90 78/73 0.74/0.76 0.41/0.32 49/53 61/53
Left wrist/right wrist 93/97 83/80 0.75/0.90 0.43/0.40 35/28 39/38
Left elbow/right elbow 96/95 87/87 0.79/0.78 0.42/0.44 20/22 31/27
Left shoulder/right shoulder 94/93 82/81 0.81/0.77 0.45/0.44 39/37 40/40
Left hip/right hip 95/95 88/83 0.80/0.83 0.52/0.40 28/29 29/33
Left knee/right knee 96/94 82/82 0.85/0.81 0.34/0.46 29/33 42/43
Left ankle/right ankle 96/95 85/91 0.83/0.79 0.47/0.62 28/28 27/22
Left toes/right toes 95/97 87/88 0.76/0.85 0.49/0.56 24/22 29/32
Neck/back 90/90 81/81 0.73/0.74 0.42/0.48 55/55 44/48
Interpretation of the weighted kappa: 0=only chance agreement, ≤0.20=poor, 0.21–0.40=fair, 0.41–0.60=moderate, 0.61–0.80=good, 
0.81–1.00=excellent/perfect.
*Retest analysis per item of severity and impact of a symptom (severity: none, mild, moderate, severe; impact: no impact, small impact, 
moderate impact, large impact).
†Percentage of patients that had the symptom at least 1 day in the past month at week 1 and month 6.
‡For each symptom answering the question: over the past month how much (symptom) have you had?
§For each symptom answering the question: what impact has this (symptom) had on the ability to carry out daily activities.
SPARRA, Symptoms in Persons At Risk of Rheumatoid Arthritis.
 o
n
 27 June 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000641 on 21 M
ay 2018. Downloaded from
 
7van Beers-tas MH, et al. RMD Open 2018;4:e000641. doi:10.1136/rmdopen-2017-000641
Rheumatoid arthritis
Comparison with FdR of patients with Ra
We compared the questionnaire data with 18 FDR of 
patients with RA. Missing data in this cohort were very 
low (1 missing question and 13 questions answered with 
two options were set on the worst case). The prevalence 
of symptoms was lower, except for numbness and change 
in skin colour (table 4). The location of joint pain was 
similar for these individuals (figure 1), just like joint 
pain patterns A, C and D (11%, 22% and 28%, respec-
tively). The percentage of pattern B was shifted towards 
the open option where individuals could fill in a pattern 
themselves (B in 5.6% and other in 33%). Of the latter 
six individuals, three had no symptoms, two had a peak 
in the beginning and then no pain and the last can be 
set as D.
dIsCussIOn
The SPARRA questionnaire has good psychometric prop-
erties. The data show a high burden, severity and impact 
of symptoms in individuals at risk of developing RA.
Evaluation of a complete set of symptoms that might be 
predictive for RA development is a challenge in the setting 
of prospective cohort studies, since questions need to be 
predetermined and are usually based on classification 
criteria. Using the SPARRA items derived directly from 
ACPA-positive symptomatic at-risk individuals gave the 
opportunity to gain more insight into these symptoms.
Questionnaires including symptoms have not yet been 
reported in cohorts researching individuals at risk of RA. 
Some use generic tools addressing functional limitations 
rather than specific symptoms, for example, the 36-item 
Short Form survey and EuroQol five dimensions ques-
tionnaire, which have shown their relevance in patients 
with RA and other musculoskeletal disease, but not yet 
in the at risk phase.31–33 Recently, the use of the Health 
Assessment Questionnaire (HAQ) has been described 
in individuals with CSA and it was shown that overall a 
low score (median 0.5) was present, but a higher score 
seemed to correlate with inflammation on MRI and 
arthritis development.17
Table 4 Duration, severity and impact of the SPARRA questionnaire items (n=237) and joint pain patterns (n=223)
Items
Duration
At least 16 days in the past month
Severity
If present, moderate/severe
Impact
If present, moderate/high impact
ACPA+ RF+ Seronegative FDR ACPA+ RF+ Seronegative FDR ACPA+ RF+ Seronegative FDR
Joint pain 37 38 72 22 63 74 72 42 51 44 56 42
Joint swelling 7 13 19 6 59 60 54 33 44 67 57 67
Joint stiffness 38 34 68 22 66 65 73 57 48 35 51 29
Burning 
sensations
11 15 21 6 69 75 60 80 56 63 48 40
Tingling 
sensations
10 8 19 6 57 78 45 75 43 44 29 25
Numbness 9 4 11 11 53 33 48 100 44 25 39 50
Change in skin 
colour
3 6 11 17 27 50 50 67 13 17 38 33
Muscle cramps 5 9 7 0 68 46 38 42 37 23 17 0
Weakness or 
loss of strength
35 21 35 22 64 63 66 50 55 48 52 33
Fatigue 39 28 33 28 84 63 63 64 70 57 53 46
Emotional 
distress
10 11 19 17 55 42 54 70 49 29 46 30
Concentration 
difficulties
17 9 14 0 64 56 65 29 56 33 61 14
Sleep problems 27 15 40 22 80 64 72 50 60 36 53 25
Joint pain 
patterns* Description of the pattern (see also table 1) ACPA+ RF+ Seronegative FDR
Pattern A Increased rapidly and then remained constant 6 10 16 11
Pattern B Gradually increased to their current level over time 15 17 21 6
Pattern C Come and gone increasing and decreasing though always with some symptoms 30 33 34 22
Pattern D Come and gone with periods without symptoms in between 32 19 16 28
Pattern E Own interpretation 17 21 13 33
Data expressed as percentages. Note that the ACPA-positive group also includes RF-positive individuals, and all RF positive individuals are 
ACPA-negative.
*Missing data in 14 individuals. 
ACPA, anticitrullinated protein antibodies; FDR, first degree relatives; RF, rheumatoid factor; SPARRA, Symptoms in Persons At Risk of 
Rheumatoid Arthritis.
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Construct validity and responsiveness of the SPARRA 
questionnaire were moderate and non-significant 
(respectively) in this study. The moderate correlation 
between clinically used VAS scores with questionnaire 
items can partly be explained by the fact that VAS scores 
measure symptoms from the past week compared with 
SPARRA questionnaire items measuring symptoms 
during the last month. Alternatively, the questions may 
measure different elements and reflect symptom content 
not captured with regular VAS pain/global assessment. 
This would mean that the questionnaire adds informa-
tion to currently available clinical measures in individuals 
at risk of RA. The low responsiveness in individuals with 
changing VAS pain and fatigue scores might relate to the 
fact that no formal cut-offs are described for this study 
population and responsiveness could only be measured 
in a small subgroup. It could be that a change in the ques-
tionnaire items is not useful in follow-up of individuals at 
risk of RA; however, future evaluation in a larger popula-
tion in a longitudinal setting is necessary.
The data showed that besides the expected joint symp-
toms, the burden of general and nervous system-related 
symptoms such as burning and tingling sensations, 
numbness and fatigue was high, especially among the 
ACPA-positive individuals. An explanation could be the 
presence of a more general subclinical inflammation as 
was suggested by MRI and PET studies29 34 as well as an 
early involvement, prior to subclinical inflammation, of 
the neurosystem in ACPA-positive individuals as both 
in-vivo and in-vitro studies have suggested.35 36 Higher 
scores in joint pain and joint stiffness in the seronegative 
individuals might be a consequence of the fact that these 
individuals were included mainly based on the presence 
of symptoms. This was underscored by a recent cohort 
study in which a difference was shown between the symp-
tomatic phase preceding ACPA-positive and ACPA-nega-
tive RA, and seronegative individuals had more symptoms 
at baseline.15 A lower burden of symptoms in the cohort 
of FDR of patients with RA was expected as these indi-
viduals mostly were without symptoms or antibodies at 
completion of the baseline SPARRA questionnaire. A 
similar joint pain location and pattern in the FDR’s as 
compared with the seropositive arthralgia group may 
reflect their increased risk for RA.16
For missing data imputation in this study, we decided 
to use a worst case scenario approach. We also checked 
whether using a best case scenario changed the results, 
which was not the case (data not shown).
A limitation of the study may be selection bias caused by 
partly using a convenience sample in which non-response 
and the associated reasons are lacking. This may have led 
to overestimation of the burden of disease, since individuals 
with more symptoms may be more willing to complete the 
questionnaire. However, since the (heterogeneous) study 
population was taken from a set of individuals found in daily 
practice in secondary care, we expect that the results from 
the study can be generalised to other secondary care prac-
tices. Also, 88% of individuals were assessed in a consecutive 
manner. Another limitation is the fact that comorbidities 
may influence the reported symptoms and data on comor-
bidities were not collected for the present study.
The predictive value of the questionnaire items (possibly 
combined with items of the HAQ) for developing RA 
requires further investigation. This can hopefully guide item 
reduction of the questionnaire in the future. Furthermore, 
responsiveness could also be investigated in medication 
trials for preventing RA and a longitudinal design would be 
helpful to assess its use.
In conclusion, this study provides evidence of good 
psychometric properties of the SPARRA questionnaire, 
except for moderate construct validity and low responsive-
ness. In individuals at risk of RA, symptoms are frequent and 
severe and have a high impact. Future studies are needed to 
evaluate whether data from the SPARRA questionnaire can 
help to improve the prediction of RA.
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